Plus Therapeutics Inc (PSTV)

1.740 -0.070 (-3.87%)
Closed USD Disclaimer

Plus Therapeutics Inc Company Profile

Equity Type
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Contact Information
Austin,78756 United States
737 255 7194
210 974 6901
Top Executives
Richard J. Hawkins 72 2007 Independent Chairman of the Board
Robert P. Lenk 73 2020 Independent Director
Vladimir P. Torchilin 74 2020 Member of Scientific Advisory Board
John C. McKew 57 2020 Member of Scientific Advisory Board
Andrew J. Brenner 0 2020 Member of Scientific Advisory Board
Marc H. Hedrick 58 2002 President, CEO & Director
An van Es-Johansson 61 2020 Independent Director
Howard Clowes 67 2020 Independent Director
Michael Vogelbaum 0 2020 Member of Clinical Advisory Board
Gregory B. Petersen 58 2020 Independent Director
Nicholas Butowski 0 2020 Member of Clinical Advisory Board
Manish Aghi 0 2020 Member of Clinical Advisory Board
Alireza Mohammadi 0 2020 Member of Clinical Advisory Board
Russell Lonser 0 2020 Member of Clinical Advisory Board
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.